Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 08/08/25
Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic ShiftsSeeking Alpha • 08/08/25
Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 EarningsZacks Investment Research • 08/06/25
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025GlobeNewsWire • 07/15/25
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®GlobeNewsWire • 07/01/25
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?Zacks Investment Research • 06/26/25
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 06/11/25
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid CancersGlobeNewsWire • 05/30/25
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 05/28/25
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 05/09/25
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?Zacks Investment Research • 05/08/25
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/01/25
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025GlobeNewsWire • 04/10/25
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell LymphomaGlobeNewsWire • 04/08/25
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell LymphomaGlobeNewsWire • 03/11/25
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 02/12/25
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/11/25